吡格列酮的疗效与PPARγ基因Pro12Ala多态性与相关性的初步研究  

A preliminary study on the association of the peroxisome proliferator-activated receptor-γ gene Pro12Ala polymorphism with the efficacy of pioglitazone

作　　者：张琦[1] 王晓霞[1] 马征[1] 王国英[1] 

机构地区：[1]北京大学第三医院内分泌科,100083

出　　处：《中国糖尿病杂志》2007年第3期164-167,共4页Chinese Journal of Diabetes

基　　金：教育部留学回国基金资助项目

摘　　要：目的探讨吡格列酮的疗效与PPARγ基因Pro12Ala多态性的关系。方法选取中国北京地区2型糖尿病(T2DM)患者112例,在原有治疗和饮食、运动保持不变的前提下,加吡格列酮30mg每天一次口服。观察10周。应用聚合酶链反应-限制性片断多态性方法进行基因型测定。结果经吡格列酮治疗后,空腹血糖(FPG)、糖化血红蛋白(HbA1c)、血清甘油三酯(TG)、收缩压和舒张压显著降低;高密度脂蛋白-胆固醇(HDL-C)和体质指数(BMI)明显增高。按PPARγ基因Pro12Ala基因型分类后发现,与治疗前比较,PP组治疗后的FPG、HbA1c、TG、收缩压和舒张压降低,HDL-C和BMI明显增高;而PA+AA组中仅FPG降低。结论吡格列酮可使T2DM患者血糖得到控制,血脂有所改善,血压下降,但亦可带来体重增加;吡格列酮的治疗效果可能与PPARγ基因Pro12Ala多态性有关。Objective To study the association of peroxisome proliferator-activated receptor-γ （PPARγ）gene Pro12Ala polymorphism with the drug efficacy of pioglitazone. Methods A total of 112 type 2 diabetic patients were treated with pioglitazone （30 mg/qd） for 10 weeks. PPARγ gene Pro12Ala polymorphism was examined by using polymerase chain reaction and restriction fragment length polymorphism （PCR-RFLP）. Results After pioglitazone treatment, the patients showed a significant decrease in FBG, HbA1c and TG, and an increase in HDL-C and BMI. Aftér stratifying by PPARγgene Pro12Ala polymorphism, there was a significant decrease in FBG, HbA1c, TG, DBP and SBP, but a significant increase in HDL-C and BMI in PP genotype group. In contrast, carriers with PA＋AA genotype experienced a significant decrease only in FBG. Conclusions Pioglitazone may reduce the levels of plasma glucose and blood pressure, improve plasma lipid in type 2 diabetic patients, but may also cause the increase in their body weights. Those efficacies of pioglitazone may be associated with PPARγgene Pro12Ala polymorphism.

关 键 词：噻唑烷二酮类 基因 PPARΓ 多态性 糖尿病 2型 

分 类 号：R587.1[医药卫生—内分泌]